Windlas Biotech Q1 FY27: Revenue up 18% YoY, PAT flat at Rs 176.5M

Results View source PDF Explain this filing

WINDLAS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+14.3%Reaction day

₹821.10

prior close

₹839.80

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.2%+14.5% vs market

Pharmaceuticals peers, median of 164sector+0.1%+14.3% vs sector

On the reaction day the stock moved 14.5 pts more than Nifty Microcap 250 and 14.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

-0.6

15m

+1.5

30m

+4.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+14.3-0.2+14.5+0.1+14.3

Next day

+9.2+0.2+9.0-0.5+9.6

+15.6+0.4+15.3+0.1+15.5

+15.7+0.4+15.3-0.5+16.2

+13.7+0.6+13.1-1.1+14.8

+12.0+0.9+11.0-0.7+12.7

+20.6+0.9+19.7-1.2+21.8

15d

+22.5+0.9+21.5-0.8+23.3

+37.6+2.3+35.2+0.9+36.6

+15.2-1.1+16.3-3.1+18.3

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Windlas Biotech reported Q1 FY27 standalone revenue from operations of Rs 2,481M, up 18% YoY from Rs 2,101M. Total income rose to Rs 2,532M. However, profit after tax was nearly flat at Rs 176.53M versus Rs 176.65M, with PBT at Rs 229.36M versus Rs 232.58M. Basic EPS stood at Rs 8.46. Company completed a Rs 470M share buyback in April 2026 and paid dividend of Rs 6.30 per share in July 2026. Wholly owned US subsidiary Windlas Inc dissolved effective March 31, 2026, so only standalone results are reported from Q1 FY27 onwards.

Likely market impact

Strong revenue growth but profits stagnated YoY. Buyback plus dividend signal healthy capital return to shareholders.